Alerts
Myeloma Patients May Not Need Treatment Forever
The ENDURANCE trial found no overall survival benefit from indefinite lenalidomide maintenance compared with stopping after two years in standard-risk, newly diagnosed multiple myeloma patients who did not undergo transplant. This is a de-escalation story with real cost and quality-of-life consequences.
Harlem’s Legionnaires’ Outbreak Was Not Just in the Air. It Was in the System.
Kenya Moves to Keep Cancer From Bankrupting Families
A Year of Measles in Utah Is What Lost Protection Looks Like
Do Not Turn Cancer Trials Into Political Collateral
A Seizure Diagnosis Should Not Automatically End a Career
Bird Flu Reached Australia. Now Preparedness Has to Deliver.
Measles Is Finding the Holes in America’s Protection Map
Gastric Cancer Gets a New Biomarker Access Signal
Brain-Bleed Care Still Has a Last-Mile Problem
Free IPM Alliance Newsletter
Insights on science, policy and access in personalised medicine.